Síndromes mieloproliferativos

Except in CML, where tyrosine kinase inhibitors (TKI) are the standard treatment, in the remaining MPD the treatment is based on cyto-reduction and control of symptoms. In some of these entities, as in primary myelofibrosis, JAK inhibitors are being used. In any case allogeneic hematopoietic stem cell transplantation remains the only curative treatment, although only a small portion of these patients can benefit from this procedure.